BioSante Pharmaceuticals Announces Panel Presentation/Webcast At the 7th Annual BIO CEO & Investor Conference
LINCOLNSHIRE, Illinois (February 22, 2005) – BioSante Pharmaceuticals (AMEX: BPA) will participate in a focus session on sexual dysfunction at the 7th Annual BIO CEO & Investor Conference being held at the Waldorf-Astoria in New York, February 23-24, 2005.
On Thursday, February 24 at 9:30 AM, Stephen M. Simes, president and chief executive officer of BioSante, will participate in a Focus Session entitled “Advances in Sexual Dysfunction and Hormone Therapies.” The discussion will address male and female sexual dysfunction programs as well as recent clinical and regulatory developments in the field of hormone therapies. In his prepared remarks Mr. Simes will discuss BioSante‰s hormone therapy products including Bio-E-Gel®, in Phase III development for reduction of hot flashes and LibiGel® moving into Phase III development in the treatment of female sexual dysfunction.
The 7th annual BIO CEO & Investor Conference is hosted by the Biotechnology Industry Organization (BIO), and brings together key industry players in a neutral and collaborative forum to examine investment opportunities and issues affecting the biotechnology industry. Participants include senior biotechnology executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at biosantepharma.cdmail.biz.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements.
Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante’s filings with the Securities and Exchange Commission, including those factors discussed on pages 18 to 25 of BioSante’s Form 10-KSB, which discussion also is incorporated herein by reference.
For more information please contact:
Harris D. McKinney, Inc.